logo-loader

Allergy Therapeutics reveal record pre-R&D operating profit with continued sales growth

Published: 08:38 23 Sep 2021 BST

Allergy Therapeutics, Allergy Therapeutics PLC (AIM:AGY, FRA:HHU)'s (LON:AGY) CEO Manuel Llobet and chief financial officer Nick Wykeman join Proactive London's Katie Pilbeam about their results for the Year ended 30 June 2021. 

The team explain their record pre-R&D operating profit which were ahead of market expectations which has been driven by continued sales growth. 

Breaking down the key drivers, the successful ex-vivo VLP peanut biomarker study showed a 24-fold reduction in allergenicity and beneficial efficacy profile which is now paving the way for first-in-human trial in 2022. 

Wykeman breaks down the numbers, with a strong cash balance of £40.3m providing sufficient funds with a small amount of debt under current assumptions to support Grass MATAL MPL pivotal Phase III field studies and Phase I VLP Peanut PROTECT trial.

Cordiant Digital Infrastructure marks three years of strategic growth and...

Cordiant Digital Infrastructure Ltd (LSE:CORD) Chairman of Digital Infrastructure Steven Marshall and Chief Financial Officer Mark Tiner joined Steve Darling from Proactive to provide some insight on the company’s three-year anniversary since listing on the London Stock Market. The company...

57 minutes ago